Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06971939 · ClinicalTrials.gov registry record · Phase 4
Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
A Phase 4 study, sponsored by Neurotech Pharmaceuticals.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 285
- Enrollment target
NCT06971939 is a Phase 4 study that is actively recruiting participants, run by Neurotech Pharmaceuticals. The registered enrollment target is 285 participants.
The verdict
NCT06971939, a Phase 4 study, is actively recruiting participants, sponsored by Neurotech Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 285 participants
- Enrollment target
Study Summary
The purpose of this global, multicenter, open-label, Phase 4 clinical extension study is to evaluate the long-term safety and efficacy of revakinagene taroretcel-lwey (Encelto™; hereinafter referred to as NT-501), in participants with macular telangiectasia type 2 (MacTel) who previously received the intraocular implant in a Phase 1, Phase 2, or Phase 3 clinical study. In addition, this study will evaluate the safety and efficacy of NT501 in participants who previously underwent the sham procedure in a Phase 3 MacTel clinical study and elect to have NT-501 implanted intraocularly in this Phase 4 study.
Interventions
- COMBINATION_PRODUCT NT-501/revakinagene taroretcel-lwey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2025-11-21 |
| Est. Completion | 2032-01-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06971939
The ClinicalTrials.gov registry entry for NCT06971939 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurotech Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NT-501/revakinagene taroretcel-lwey is the first listed.
NCT06971939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06971939 about?
NCT06971939 is a clinical study titled "Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants". The purpose of this global, multicenter, open-label, Phase 4 clinical extension study is to evaluate the long-term safety and efficacy of revakinagene taroretcel-lwey (Encelto™; hereinafter referred to as NT-501), in participants with macular telangiectasia type 2 (MacTel) who previously received th...
What is the current status of trial NCT06971939?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 285 participants. The study started on 2025-11-21. Estimated completion is 2032-01-15.
What interventions are being tested in trial NCT06971939?
The interventions under investigation include: NT-501/revakinagene taroretcel-lwey (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06971939?
This trial is sponsored by Neurotech Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.